Major pharmaceutical companies continually research and develop new cancer drugs and treatments, which must be shown to be safe and effective before doctors can prescribe them to patients. Through lymphomaclinical trials, researchers test the effects of new medications on a group of volunteers with lymphoma. Following a strict protocol and using carefully controlled conditions, researchers evaluate the drugs under development and measure the ability of the new drug to treat lymphoma, its safety, and any possible side effects.
Some patients with lymphoma are reluctant to take part in clinical trials for fear of getting no treatment at all for their lymphoma. This is simply not true. Patients with lymphoma who participate in lymphoma clinical trials receive the most effective therapy currently available for their condition -- or they may receive lymphoma treatments that are being evaluated for future use. These lymphoma treatments may be even more effective than currently available lymphoma treatments. The only way to determine if the newer treatment is better than currently available treatments is by clinical trial participation.
Antineoplastons are chemical compounds that are found normally in urine and blood. For use in medical research, antineoplastons can be made from chemicals in a laboratory. (See Question 1.)
Antineoplaston therapy was developed by Dr. S. R. Burzynski, who proposed the use of antineoplastons as a possible cancer treatment in 1976. (See Question 2.)
No randomized, controlled trials showing the effectiveness of antineoplastons have been published in peer-reviewed scientific journals. (See Question...
This web site, developed by the nonprofit Coalition of Cancer Cooperative Groups, is an unbiased cancer clinical trial matching and navigation service enabling patients to search for cancer trials based on disease and location.